Current share price for S66 : $0.120 0.01 (7.69%)+
Star Combo Pharma Ltd (S66), an ASX-listed company, is involved in the manufacture and distribution of health food products and nutritional supplements.
| ASX Code | S66 |
| Website | http://www.starcombo.com.au |
| Industry/Sector | Personal Products |
| Market Cap ($M) | 16 |
| S66 Share Price | $0.120 |
| Day High | $0.125 |
| Day Low | $0.120 |
| Last Close | $0.130 |
| S66 Share Price Movement | $0.01 ( 7.69% ) |
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| HFResult | 0.37¢ | 100% | 14 Oct 2025 | 31 Oct 2025 | - | - | - |
| HFResult | 0.37¢ | 100% | 14 Oct 2024 | 31 Oct 2024 | - | - | - |
See all dividends from Star Combo Pharma Limited (S66) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | $5.25 | $3.90 | 607.30% | 3.60 | 0.00 | 0.00% | 100.0% |
| 2024A | $0.75 | $0.60 | 71.90% | 22.30 | 0.40 | 3.00% | 100.0% |
| 2023A | $0.44 | $0.30 | -49.20% | 48.80 | 0.00 | 0.00% | 0.0% |
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Star Combo Pharma Limited (S66) | $18M | 6.0727 | 0.0000 | 0.0000 | 3.3419 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.20 | 3.34 | 0.46 | 0.00 |
| Market | 0.30 | 13.20 | 1.18 | 0.68 |
| Sector | 0.00 | 44.30 | 0.85 | 0.00 |
| Name | Position | Start Date |
|---|---|---|
| Ms Su Zhang | Chief Executive Officer, Executive Director | 4 Nov 2016 |
| Mr Star (JinXing) Zhang | Managing Director | 4 Nov 2016 |
| Mr Richard Ivan Allely | Non-Executive Chairman, Non-Executive Director | 2 Feb 2018 |
| Ms Wei Han | Non-Executive Director | 29 May 2020 |
| Mr Jialong Ding | Non-Executive Director | 29 May 2020 |
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|
See all changes in directors' interest & trades for Star Combo Pharma Limited (S66) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
| Name | Position |
|---|---|
| James Ni | Chief Financial Officer |
| Patrick Raper | Company Secretary |
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Star Combo Pharma Limited (S66). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 49,000,000 (36.27%) | Goldenstar Pharmaceutical Investment Limited |
| 38,165,510 (28.25%) | Jinxing Star Zhang |
| 11,448,980 (8.48%) | Su Zhang |
| 11,000,000 (8.14%) | Lepu Medical Europe Cooperatief UA |
| Date | Event |
|---|---|
| 24 February 2027 | Report (Interim) |
| 23 October 2026 | Report (Annual) |
| 25 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.